Cargando…

ESR1 fusions and therapeutic resistance in metastatic breast cancer

Breast cancer is the most frequent female malignant tumor, and the leading cause of cancer death in women worldwide. The most common subtype of breast cancer is hormone receptor positive that expresses the estrogen receptor (ER). Targeting ER with endocrine therapy (ET) is the current standard of ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagy, Zsuzsanna, Jeselsohn, Rinath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848494/ https://www.ncbi.nlm.nih.gov/pubmed/36686845 http://dx.doi.org/10.3389/fonc.2022.1037531

Ejemplares similares

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
por: Kuang, Yanan, et al.
Publicado: (2018)

How drug resistance takes shape
por: Jeselsohn, Rinath, et al.
Publicado: (2016)

Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
por: Liao, Hao, et al.
Publicado: (2020)

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
por: Li, Li, et al.
Publicado: (2020)

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
por: Fanning, Sean W, et al.
Publicado: (2018)

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
por: Gerratana, Lorenzo, et al.
Publicado: (2020)

ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

Elucidation of Novel Therapeutic Targets for Breast Cancer with ESR1-CCDC170 Fusion
por: Jeong, Jae Heon, et al.
Publicado: (2021)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
por: Reinert, Tomas, et al.
Publicado: (2017)

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
por: Hartmaier, R J, et al.
Publicado: (2018)

ESR1 mutations in metastatic lobular breast cancer patients
por: Desmedt, Christine, et al.
Publicado: (2019)

RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
por: Dustin, Derek, et al.
Publicado: (2020)

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
por: Downton, Teesha, et al.
Publicado: (2022)

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
por: Urso, Loredana, et al.
Publicado: (2021)

microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer
por: Gao, Shan, et al.
Publicado: (2020)

Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
por: Li, Zheqi, et al.
Publicado: (2022)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo
por: Piperigkou, Zoi, et al.
Publicado: (2022)

Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2021)

DNAJC12 as a Mediator Between ESR1 and ERBB4 in Breast Carcinoma Cells
por: Lin, Mianjie, et al.
Publicado: (2021)

Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis
por: Najim, Omar, et al.
Publicado: (2023)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

Unusual phylogenetic tree and circulating actionable ESR1 mutations in an aggressive luminal/HER2-low breast cancer: Case report
por: Allegretti, Matteo, et al.
Publicado: (2023)

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer
por: Gou, Xuxu, et al.
Publicado: (2023)

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
por: Lei, Jonathan T., et al.
Publicado: (2018)

The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
por: Vitale, Silvia R., et al.
Publicado: (2022)

ESR1 mutations in breast cancer
por: Clatot, Florian, et al.
Publicado: (2017)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
por: Harrod, A, et al.
Publicado: (2017)

Expression Analysis of Long Non-Coding RNAs Related With FOXM1, GATA3, FOXA1 and ESR1 in Breast Tissues
por: Hassani, Bita, et al.
Publicado: (2021)

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
por: Cheng, Xuan, et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
por: Niu, Jiaxin, et al.
Publicado: (2015)

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
por: Brett, Jamie O., et al.
Publicado: (2021)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
por: Berger, Frédérique, et al.
Publicado: (2022)

ESR1 ligand binding domain mutations in hormone-resistant breast cancer
por: Toy, Weiyi, et al.
Publicado: (2013)

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
por: Zhang, Kai, et al.
Publicado: (2018)

ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma
por: Zhang, Yiyin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6s6g5gvvu7b6je7omnmis3l7ub